Exploration of critical parameters for transient retrovirus production

被引:26
作者
Bajgelman, MC
Costanzi-Strauss, E
Strauss, BE
机构
[1] Univ Sao Paulo, Dept Histol & Embryol, Inst Biomed Sci, Sao Paulo, Brazil
[2] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil
[3] Univ Sao Paulo, Ctr Biotechnol, Inst Biomed Sci, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
pCL; pAdvantage; transfection; titration; beta-galactosidase;
D O I
10.1016/S0168-1656(03)00103-2
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The pCL system was developed to aid in the production of retrovirus that encodes cytotoxic or cytostatic cDNA's. A principal feature of this system is the transient production of virus after co-transfection of the viral and packaging vectors in the 293T cell line. This approach obviates the need for selection of the producer cells, thus minimizing potential affects of the encoded genes. However, the transient nature of this system also creates a number of experimental variables. In this study we have examined and optimized elements related to the production of the pCL retrovirus. For example, co-transfection of the packaging sequence along with the viral vector has been optimized in terms of both the total amount of DNA transfected and the relative proportion of each plasmid. We have also tested the affect of increased synthesis of viral proteins in the producer cells and the kinetics of virus accumulation in the supernatant. These findings may be of interest to those who use pCL or any transient packaging system in their gene transfer studies. In addition, these studies may aid in the validation and development of transient retrovirus production systems for clinical applications. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:97 / 106
页数:10
相关论文
共 21 条
[1]  
Anderson WF, 1998, NATURE, V392, P25
[2]   Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines [J].
Costanzi-Strauss, E ;
Strauss, BE ;
Naviaux, RK ;
Haas, M .
EXPERIMENTAL CELL RESEARCH, 1998, 238 (01) :51-62
[3]   Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium [J].
Gerin, PA ;
Gilligan, MG ;
Searle, PF ;
Al-Rubeai, M .
HUMAN GENE THERAPY, 1999, 10 (12) :1965-1974
[4]   Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18 [J].
Gerin, PA ;
Searle, PF ;
Al-Rubeai, M .
BIOTECHNOLOGY PROGRESS, 1999, 15 (05) :941-948
[5]   Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium [J].
Glimm, H ;
Flügge, K ;
Möbest, D ;
Hofmann, VM ;
Postmus, J ;
Henschler, R ;
Lange, W ;
Finke, J ;
Kiem, HP ;
Schulz, G ;
Rosenthal, F ;
Mertelsmann, R ;
von Kalle, C .
HUMAN GENE THERAPY, 1998, 9 (06) :771-778
[6]  
Kafri T, 2001, CURR OPIN MOL THER, V3, P316
[7]   AN ADENOVIRUS MUTANT UNABLE TO EXPRESS VAI-RNA DISPLAYS DIFFERENT GROWTH-RESPONSES AND SENSITIVITY TO INTERFERON IN VARIOUS HOST-CELL LINES [J].
KITAJEWSKI, J ;
SCHNEIDER, RJ ;
SAFER, B ;
SHENK, T .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (12) :4493-4498
[8]   ADENOVIRUS VAI RNA ANTAGONIZES THE ANTIVIRAL ACTION OF INTERFERON BY PREVENTING ACTIVATION OF THE INTERFERON-INDUCED ELF-2-ALPHA KINASE [J].
KITAJEWSKI, J ;
SCHNEIDER, RJ ;
SAFER, B ;
MUNEMITSU, SM ;
SAMUEL, CE ;
THIMMAPPAYA, B ;
SHENK, T .
CELL, 1986, 45 (02) :195-200
[9]  
Le Doux JM, 1998, BIOTECHNOL BIOENG, V58, P23, DOI 10.1002/(SICI)1097-0290(19980405)58:1<23::AID-BIT3>3.3.CO
[10]  
2-S